This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Incyte (INCY) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Incyte (INCY) has a mixed track record. Investors will focus on Jakafi sales and other pipeline updates when the company reports its Q2 results on Jul 31.
Glaxo (GSK) Q2 Earnings & Sales Beat Estimates, '18 View Up
by Zacks Equity Research
Glaxo (GSK) beats both earnings and revenues in the second quarter of 2018, and signs a four-year collaboration with 23andMe and invests $300 million for the same.
Gilead (GILD) Q2 Earnings & Sales Beat Eclipsed by CEO Exit
by Zacks Equity Research
Gilead's GILD) stock is down in after-market trading as the news of departure of the company's CEO has overshadowed the company's second-quarter results, which beat estimates.
Lilly (LLY) Tops Q2 Earnings, Chooses IPO Path for Elanco
by Zacks Equity Research
Eli Lilly (LLY) tops estimates for both earnings and sales in the second quarter and raises guidance for 2018. It will divest its Elanco unit into a new public company. Stock up in pre-market trading.
Pharma/Biotech Stock Q2 Earnings on Jul 25: GILD, VRTX & GSK
by Zacks Equity Research
The going has been good for the pharma giants, which reported second-quarter results so far. Let us see what is in store for biotech bigwig GILD, VRTX and large-cap pharma company GSK.
What's in the Cards for Glaxo (GSK) This Earnings Season?
by Zacks Equity Research
Glaxo's (GSK) Pharmaceuticals and Vaccines segments are likely to boost sales in Q2 earnings.
Amgen (AMGN) to Report Q2 Earnings: Will it Beat Again?
by Zacks Equity Research
While Amgen's (AMGN) growth drugs like Prolia & Xgeva might do well, biosimilar competition and slowdown in sales of mature products can put pressure on sales growth.
BIIB, LLY Q2 Earnings on Jul 24: Here are the Key Predictions
by Zacks Equity Research
Two large pharma/biotech companies have reported so far, displaying strong sales trend. Let's see how Lilly (LLY) and Biogen (BIIB) are poised ahead of their scheduled results tomorrow.
The Zacks Analyst Blog Highlights: Microsoft, Novartis, Goldman Sachs, Starbucks and General Motors
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Microsoft, Novartis, Goldman Sachs, Starbucks and General Motors
Merck to Cut Price of Few Drugs Amid Drug Pricing Controversy
by Zacks Equity Research
Merck (MRK) announces a 60% cut in U.S. list prices for its hepatitis C drug, Zepatier. It will also lower the list price of some other drugs by 10%.
Pharma Stock Roundup: JNJ & NVS' Q2 Earnings, FDA Approvals
by Zacks Equity Research
J&J (JNJ) and Novartis (NVS) kick off earnings for pharma sector on a strong note. FDA approves J&J's latest HIV medicine and line extension of Pfizer's prostate cancer drug.
Top Research Reports for Microsoft, Novartis & Goldman Sachs
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Microsoft (MSFT), Novartis (NVS) and Goldman Sachs (GS).
Novartis' (NVS) Kisqali Gets FDA Nod for Label Expansion
by Zacks Equity Research
Novartis' (NVS) breast cancer drug, Kisqali, gets FDA approval as first-line treatment for pre-, peri- or post-menopausal women with HR+/HER2- advanced breast cancer.
Roche's Tecentriq Met Primary Goal in First-Line NSCLC Study
by Zacks Equity Research
Roche's (RHHBY) late-stage lung cancer study on immuno-oncology drug, Tecentriq, meets its co-primary endpoint of progression-free survival (PFS).
Novartis Q2 Earnings Miss, Sales Top on Cosentyx, Entresto
by Zacks Equity Research
Novartis (NVS) misses on Q2 earnings but beats sales on the back of continued momentum from Cosentyx and Entresto. Oncology franchise also exhibits strong growth.
Novartis (NVS) Stock Flat Ahead of Earnings: What To Watch
by Ryan McQueeney
Shares of Novartis (NVS) added just 0.14% during regular hours Tuesday, the last day of trading before the pharma giant releases its latest quarterly earnings report. Here's what to expect tomorrow morning.
Roche's Flu Drug Meets Primary Endpoint in Phase III Study
by Zacks Equity Research
Roche (RHHBY) announces that its antiviral candidate, baloxavir marboxil, met the primary endpoint in a phase III study in patients suffering from risk of complications from the flu.
Is a Surprise in the Cards for Novartis in Q2 Earnings?
by Zacks Equity Research
Swiss-giant Novartis (NVS) is all set to report second-quarter 2018 earnings on Jul 18. While the pharma business should maintain growth, the generic division is expected to be laggard.
The Zacks Analyst Blog Highlights: Johnson & Johnson, Novartis, UnitedHealth and Microsoft
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Novartis, UnitedHealth and Microsoft
Novartis Looks to Exit Antibacterial, Antiviral Program
by Zacks Equity Research
Per media sources, Novartis is looking to exit its antibacterial and antiviral research program, and cut its headcount.
JNJ vs. NVS: Which Stock is Better Pre Q1 Earnings?
by Zacks Equity Research
With Johnson & Johnson (JNJ) and Novartis AG (NVS) scheduled to report on Jul 17 and Jul 18, respectively, this may be a good time to figure out which of these is a better stock.
3 Gene Therapy Stocks Investors Can Bet on in Rest of 2018
by Ekta Bagri
Gene therapy continues to be in focus with the recent spate of deals and acquisitions. We highlight three stocks, which have promising candidates in their pipeline.
Pharma Stock Roundup: NVS to Divest Eye Care Unit, CHMP Gives Nod to Several Drugs
by Zacks Equity Research
Novartis (NVS) intends to spin off its Alcon eye care division. The CHMP gives positive opinion recommending marketing approval to several drugs.
Adamis (ADMP) Surges Following Novartis Deal for Symjepi
by Zacks Equity Research
Shares of Adamis (ADMP) skyrocket after the company signs a commercialization deal with Novartis for Symjepi.
Novartis to Spin-Off Alcon as Separate Trading Company
by Zacks Equity Research
Novartis announces that it will spin-off its ophthalmology division, Alcon, into a separately-traded standalone company in order to focus on its legacy pharmaceuticals business.